

## Supplementary data

**Table I Treatments and outcomes in literatures**

	Journal	N	Treatments	Outcomes				
				Fluctuations treatments	after	at 24 hours	(or discharge)	Follow-up
1	Intern Med. 2017 <sup>1</sup>	1	Step 1: argatroban (60 mg), aspirin (100 mg), cilostazol (200 mg), atorvastatin (10 mg), and edaravone (60 mg/day); Step 2: rt-PA 80mg	treatments in Step 1 were not effective; no more episode after rt- PA		NIHSS 0 with slight right hemiparesis	/	
2	Neurologist. 2016 <sup>2</sup>	2	Permissive hypertension	/		/		partial resolution
3	Neuroradiol 2016 <sup>3</sup>	J. 1	t-PA	new episodes and suffered a respiratory failure		Locked-in		remaining the locked-in syndrome

4	J Neurol Sci. 2015 <sup>4</sup>	1	argatroban (60 mg), low molecule dextran and edaravone (60 mg), clopidogrel (75 mg), aspirin and cilostazol (400 mg)	The frequency and magnitude gradually attenuated	/	/
5	Int J Stroke, 2015 <sup>5</sup>	42	12 patients (28.6%) received rt-PA, other therapy including antiplatelet, vasopressors, anticoagulant therapy	/	A favorable functional outcome at discharge was observed in 36 patients (85.7%)	Nine patients (75%) who received rt-PA and 100% of patients who did not received rt-PA had favorable outcomes
6	J Cerebrovasc Dis. 2014 <sup>6</sup>	1	Step 1: aspirin(200mg/day),cilostazol(200mg/d),atorvastatin(5mg/d),argatroban ,edaravone+plasma expander Step 2: Loading dose clopidogrel(300mg)	Several TIAs occurred repeatedly after step 1. After step 2, three more attacks occurred for 2 hours then no further TIAs thereafter.	Discharged without neurologic deficit 16 days later.	/
7	Neurologia, 2014 <sup>7</sup>	3	rt-PA	/	NIHSS=1 in 2patients NIHSS=0 in 1 patient	mRS 0 at 3months

8	J Neurol Transl Neurosci. 2014 <sup>8</sup>	7	Clopidogrel 300mg	/	Four the patients had complete resolution. The others were discharged with mild persistent symptoms.	/
9	J Neurol Sci. 2013 <sup>9</sup>	9	rt-PA	Neurological symptoms were fluctuating during rt-PA administration and the course of the next 24 hours in 7 patients	NIHSS median was 7(6-9) at discharge	mRs 0-2 in 33% patients
		9	Non-rt-PA	/	NIHSS median was 2.5(0-9.2)at discharge	mRs 0-2 in 55% patients
10	BMJ Case Rep. 2013 <sup>10</sup>	1	Aspirin 300 mg/d, simvastatin 40mg/d, amlodipine 5mg plus clopidogrel 300mg	Further more severe symptoms	0/5 power in right upper limb; 3+/5 in right lower limb; weakness in right face	was able to walk with the aid of a stick at 6 months
11	Neurologia , 2013 <sup>11</sup>	1	rt-pa	New episode	NIHSS 8 at discharge (8 days later)	/

12	Cerebrovasc Dis,2013 <sup>12</sup>	1	tPA	Continued to fluctuate per day for 5 days	/	Subtly apparent
13	J Clinical Neuroscience, 2012 <sup>13</sup>	1	aspirin, high dose of statin,hydration,heperin	2 further episodes and definite dense hemiplegia;	dense hemiplegia	Mild hand paresis after 4 months
14	Neurologist. 2012 <sup>14</sup>	2	clopidogrel 300mg ,aspirin 300mg,IV hydration	No more attacks	Complete recovery	/
15	J Neurol Sci. 2010 <sup>15</sup>	1	Step 1:Intravenous heparin for 6 days, then aspirin 325mg/d and clopidogrel 75mg/d( after loading dose of 225mg) Step 2: Angioplasty	Continued to have TIAs after heparin plus aspirin and clopidogrel No more additional TIAs following angioplasty	/	No symptom at 3 months
16	BMC Neurol. 2010 <sup>16</sup>	1	clopidogrel,atorvastatin	Lasting hemiplegia without recovery	NIHSS 5 at discharge (23 days later)	/
17	Rinsho Shinkeigaku. 2010 <sup>17</sup>	1	aspirin, heparin, atorvastatin and t-PA, plasma expander	symptoms occurred repeatedly for 22 hours	No deficit at 24 hours	/

18	J Cerebrovasc Dis. 2010 <sup>18</sup>	Stroke	11	antiplatelet agents; one patient with tPA	Symptomatic fluctuation lasted for 1-7 days	/	/
19	Arch Neurol., 2008 <sup>19</sup>		1	tPA	Fluctuated for 12 hours after receiving thrombolytic therapy	NIHSS score is 12 at discharge	/
20	Cerebrovasc Dis.2008 <sup>20</sup>		4	t-PA	3/4 patients recovered without new episodes;	NIHSS score=0 at discharge in 3 patients;1 patient with persistent deficit(NIHSS=12)	
21	Neurocrit Care. 2005 <sup>21</sup>		2	Patient 1: aspirin 325 mg, clopidogrel 300 mg Patient 2: clopidogrel 300 mg , aspirin 81 mg	No further episodes	No lasting deficit	/
22	Stroke, 1993 <sup>22</sup>		1	heparin	fluctuations stopped 3 days later	0/5 power in arm and leg, with persisting dysarthria	3/5 power after 3 weeks

## Reference

1. Fuseya Y, Kawamura M, Matsuda E, et al. rt-PA with Antithrombotic Therapies in a Case with Capsular Warning Syndrome. *Internal Medicine* 2017;56(4):441.
2. Enriquez-Marulanda A, Amaya-Gonzalez P, Orozco JL. Pontine Warning Syndrome: A Chameleon of Ischemic Stroke. *Neurologist* 2016;21(6):93-96.
3. Garcia-Esperon C, Lopez-Cancio E, Martin-Aguilar L, et al. Fluctuating locked-in syndrome as a presentation of a bilateral pontine infarction. *Neuroradiol J* 2016;29(5):347-9. doi: 10.1177/1971400916658896
4. Makita N, Yamamoto Y, Nagakane Y, et al. Very prolonged capsular warning syndrome. *Journal of the Neurological Sciences* 2015;352(1-2):115.
5. Campsrenom P, Delgadomederos R, Martínezdomeño A, et al. Clinical characteristics and outcome of the capsular warning syndrome: a multicenter study. *International Journal of Stroke* 2015;10(4):571-75.
6. Kawano H, Nakajima M, Inatomi Y, et al. Loading dose of clopidogrel in combination with other antithrombotic therapy for capsular warning syndrome. *Journal of Stroke & Cerebrovascular Diseases* 2014;23(5):1265-66.
7. Gonzalez Hernandez A, Fabre Pi O, Cabrera Naranjo F, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator in vascular warning syndromes. *Neurologia* 2014;29(6):334-8. doi: 10.1016/j.nrl.2013.07.005
8. Marsh EB, Llinas RH. Stuttering Lacunes: An Acute Role for Clopidogrel? *Journal of Neurology & Translational Neuroscience* 2014;2(1)
9. Rossana T, Alfonso C, Maurizio A, et al. Stroke warning syndrome: 18 new cases. *Journal of the Neurological Sciences* 2013;331(1-2):168-71.
10. Nadarajan V, Adesina T. Capsular warning syndrome. *Bmj Case Rep* 2013;2013(2013)

11. Gutiérrez RB, García PA, Villanueva Osorio JA, et al. [Intravenous thrombolysis in capsular warning syndrome: is it beneficial?]. *Neurología* 2013;28(7):444-6.
12. Springer MV, Labovitz DL. The Capsular Warning Syndrome Reconsidered. *Cerebrovascular Diseases* 2013;36(2):152-52.
13. Paul NLM, Simoni M, Chandratheva A, et al. Population-based study of capsular warning syndrome and prognosis after early recurrent TIA. *Neurology* 2013;57(1):1356-62.
14. Asil T, Ir N, Karaduman F, et al. Combined antithrombotic treatment with aspirin and clopidogrel for patients with capsular warning syndrome: a case report. *Neurologist* 2012;18(2):68.
15. Lee J, Albers GW, Marks MP, et al. Capsular warning syndrome caused by middle cerebral artery stenosis. *Journal of the Neurological Sciences* 2010;296(1–2):115-20.
16. Huang HW, He SW, Tan SQ, et al. Patient with pontine warning syndrome and bilateral posterior internuclear ophthalmoplegia: case report. *Bmc Neurology* 2010;10(1):1-4.
17. Taguchi Y, Takashima S, Nukui T, et al. [Case of branch atheromatous disease presenting capsular warning syndrome]. *Rinsho Shinkeigaku* 2010;50(5):320-24.
18. Chen ZC, Hu XY, Zhou JJ, et al. Clinical analysis of 11 patients with capsular warning syndrome. 2010
19. Saposnik G, Noel dTL, Caplan LR. Pontine warning syndrome. *Archives of Neurology* 2008;65(10):1375-7.
20. Vivancohidalgo RM, Rodriguezcampello A, Ois A, et al. Thrombolysis in Capsular Warning Syndrome. *Cerebrovascular Diseases* 2008;25(5):508-10.
21. Fahey CD, Alberts MJ, Bernstein RA. Oral clopidogrel load in aspirin-resistant capsular warning syndrome. *Neurocritical Care* 2005;2(2):183-84.

22. Donnan GA, O'Malley HM, Quang L, et al. The capsular warning syndrome: pathogenesis and clinical features. *Neurology* 1993;43(5):957-62.